Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13454MR)

This product GTTS-WQ13454MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13454MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3072MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ11883MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ7852MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ8547MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ942MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ14932MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ15456MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ6726MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW